ABSTRACT
INTRODUCTION
Glaucoma is a chronic disease and still a major cause of blindness. Most patients with glaucoma must use ocular hypotensive drugs continuously throughout their life. However, since glaucoma is relatively asymptomatic in the early stage, the low adherence to ophthalmic solutions for anti-glaucoma was reported [1] . Poor adherence raises the risk of the progression of visual field defects [2] and also the risk of blindness in glaucoma patients [3] .
Nowadays, although prostaglandin analogs (PGAs) or b-blockers are used in the first-line therapy because of their potent ocular hypotensive effects, there are many patients treated with the concomitant use of two or more drugs [4] . The concomitant therapy for glaucoma may cause a decrease in the adherence due to complicated dosing regimens, weaken the hypotensive effects with wash-out effects with a short instillation interval (less than 5 min), and cause corneal and/or conjunctival disorders by an increase in the amount and frequency of preservative exposure [5] . Therefore, a fixed combination therapy, when available, should be preferable to two separate instillations of agents [5] .
A fixed combination of tafluprost (0.0015%) and timolol maleate (0.5%) (Tapcom Taf-TFC is not inferior to concomitant use of the two active drugs [6] and is superior to either agent alone [6, 7] . Based on these findings, Taf-TFC was approved in Japan in 2014, and it is also marketed in Europe as a preservative-free solution (Tapticom, Santen Oy, Finland). However, typically, the patients in the pivotal clinical studies are limited in terms of the type and severity of glaucoma, associated diseases, and concomitant medications. In addition, treatment was administered under stringent control. To obtain more additional information in real-world setting, a post-marketing study needs to be performed using various treatment regimens in a wider variety of patients to evaluate the efficacy and safety of Taf-TFC in routine clinical practice. Accordingly, Santen is currently conducting a long-term observational study with an up to 2-year (more than 1 year) follow-up period in a large population of more than 1000 patients. This report presents the short-term results obtained with Taf-TFC in various clinical settings based on analysis of the data up to 3 months.
METHODS

Study Design
A multicenter, prospective, non-interventional, observational post-marketing study is being conducted in accordance with the requirements of the Japanese regulatory authority (Good Post-Marketing Study Practice, Ministry of Health, Labor and Welfare Ordinance No. 171; December 20, 2004) . The study commenced in January 2015 and is scheduled to run until September 2018. Since the protocol was reviewed and approved by the Japanese regulatory authority prior to initiation of the study, approval by the ethics committee at each participating institution was not required.
Patients and Registration
The inclusion criteria for this study are patients with glaucoma or OH who had not previously been treated with Taf-TFC. A central registration system is used to avoid selection bias. When a patient meets the inclusion criteria, the participating physician registers the patient by facsimile within 2 weeks of prescribing Taf-TFC. Since the Japanese regulatory authority does not require informed consent for post-marketing observational studies, informed consent is not obtained from the patients. The observation period has been set as up to 2 years (more than 1 year) after starting treatment with Taf IOP intraocular pressure, NTG normal tension glaucoma, OH ocular hypertension, PACG primary angle-closure glaucoma, POAG primary open-angle glaucoma, SD standard deviation although the ''Naïve'' group had a higher proportion of patients aged 30-39 years and with a baseline IOP of 25 mmHg or over.
Previous medications varied widely in the ''switched'' group, including PGA monotherapy (n = 145, 54.5%), PGA and b-blocker (timolol, carteolol, etc.) concomitant therapy (n = 34, 12.8%), b-blocker (timolol, carteolol, etc.) monotherapy (n = 28, 10.5%), and monotherapy with another fixed combination of PGA and timolol (PGA-TFC) (n = 51, 19.2%).
Adverse Drug Reactions
There were 25 adverse events classified as ADRs in 22 patients (5.01%) ( Table 2 ). ADRs were local (affecting the eye) in 20 events and systemic in 5 events. The major ADRs were conjunctival hyperemia (5 events), blepharitis (4 events), and punctate keratitis (2 events). The serious ADR were recognized in 2 patients (3 events); blood pressure increased, asthenic conditions (physical deconditioning), and chest discomfort (one each). (n = 234) at 2 months, and 0.1 ± 0.4 (n = 232) at 3 months. There were no significant changes of these scores at any time.
IOP-Lowering Effect
Of the 439 patients, IOP data were analyzed in 410 patients in whom the IOP was measured In the ''Naïve'' group, the mean IOP was 18.6 ± 6.1 mmHg at baseline (n = 59), and it was significantly reduced at 1, 2, and 3 months (-4.9 ± 3.3, -4.3 ± 3.0, and -5.1 ± 3.0 mmHg, respectively, P\0.001, paired t-test, Table 3 , Fig. 3 ). In the ''Switched'' group, mean IOP was 17.0 ± 4.2 mmHg at baseline (n = 267), and it was also significantly reduced at 1, 2, and 3 months (-2.1 ± 2.7, -2.5 ± 3.1, and -2.4 ± 3.1 mmHg, respectively, P\0.001, paired t-test, Table 3 , Fig. 3 ). In the ''Concomitant'' group, mean IOP was
18.2 ± 6.4 mmHg at baseline (n = 84), and it likewise showed a significant decrease at 1, 2, and 3 months (-4.5 ± 6.9, -3.9 ± 6.9, and -4.6 ± 6.9 mmHg respectively, P\0.001, paired t-test, Table 3 , Fig. 3 ).
In patients switched from PGA monotherapy to Taf-TFC monotherapy, mean IOP was 17.4 ± 4.0 mmHg at baseline (n = 137), and it declined significantly at 1, 2, and 3 months after switching (-2.8 ± 2.1, -3.1 ± 3.2, and -2.9 ± 3.3 mmHg, respectively, P\0.001, paired t-test, Table 4 , Fig. 4 ). The IOP reduction was similar in patients switched from latanoprost, travoprost or tafluprost to Taf-TFC monotherapy (Fig. 5) . Among patients switched from PGA monotherapy, IOP reduction C2 mmHg was defined as ''improved,'' change of the IOP within 2 mmHg was defined as ''unchanged,'' and an increase in IOP by C2 mmHg was defined as ''worse.'' As a result, 64.3% of patients were ''improved,'' 31.0% were ''unchanged,'' and 4.8% were ''worse'' (Fig. 6) . At 3 months, improvement was noted in 17 patients (70.8%)
switched from latanoprost (n = 24), 24 patients (60.0%) switched from tafluprost (n = 40), and 5 patients (55.6%) switched from travoprost (n = 9). In patients switched from b-blocker (timolol, carteolol, etc.) monotherapy to Taf-TFC monotherapy, mean IOP was 16.7 ± 3.7 mmHg at baseline (n = 25), and it was significantly Taf-TFC (-2.5 ± 1.9, -2.6 ± 2.5, and -4.1 ± 2.1 mmHg, respectively, P\0.05, paired t-test) ( Table 4 ; Fig. 4 ). In patients switched from PGA and b-blocker (timolol, carteolol, etc.) combined therapy to Taf-TFC monotherapy, mean IOP was 15.1 ± 2.9 mmHg at baseline (n = 31) and did not change significantly up to 3 months of Taf-TFC treatment (paired t-test, Table 4 , Fig. 4 ).
On the other hand, in patients with switched from other PGA-TFC to Taf-TFC monotherapy, mean IOP was 18.0 ± 4.9 mmHg at baseline, and it was significantly reduced at 1, 2, and 3 months after switching to Taf-TFC (-1.6 ± 2.2, -1.9 ± 2.3, and -1.3 ± 3.1 mmHg, respectively, P\0.05, paired t-test, Table 4 , Fig. 4 ). The decrease in IOP with Taf-TFC monotherapy was similar in patients switched from the latanoprost/timolol combination IOP intraocular pressure, Taf-TFC tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution a ' 'Naïve,' ' no previous treatment or concomitant drugs b ' 'Switched,'' switched to Taf-TFC monotherapy after treatment with at least one previous drug c ' 'Concomitant,' ' addition of/switching to Taf-TFC combined with other anti-glaucoma medications (Lat-TFC) or travoprost/timolol combination (Tra-TFC) drug, but a significant reduction was not observed in the former patients at 1 month and in the latter patients at 3 months (Table 4 , Fig. 7) . At 3 months, six patients (46.2%)
switched from Lat-TFC (n = 13) and six patients (50.0%) switched from Tra-TFC (n = 12) were classified as ''improved'' (Fig. 8) The majority of patients in this study had NTG or POAG, accounting for more than 80% of the subjects combined. The Tajimi Study, an epidemiological study conducted in Japan by the Japan Glaucoma Society, found that 72% of glaucoma patients had NTG [8, 9] . Almost half of the glaucoma patients in our study had NTG, also showing that NTG is common among Japanese glaucoma patients. Besides patients with NTG, POAG, and OH, our study included patients with PACG, who have not been thoroughly investigated in previous clinical trials. Taf-TFC significantly reduced IOP in patients with NTG, POAG, and OH, and it also IOP change (mmHg) -1.3 ± 2.5 -1.9 ± 2.6 -1.5 ± 2.5 tended to reduce IOP in PACG patients. These results suggest that Taf-TFC is effective for treating a wide variety of types of glaucoma in actual clinical practice. In this study, the incidence of ADR was 5.01%, which was lower than in previous interventional clinical studies [6, 7] . This may have been related to differences in the extent of clinical monitoring for adverse events between an interventional clinical study and daily clinical practice. In this study, serious ADRs were observed in two patients. While uncommon, serious ADRs must be considered when starting Taf-TFC. The incidence of ADRs in this study was also lower than that reported in a post-marketing study of Lat-TFC in Japan (9.9%) [10] . Since this interim report only covers a 3-month period, the incidence of In this study, Taf-TFC significantly reduced the IOP. In the Japanese phase III clinical study, the efficacy of Taf-TFC was significantly greater than that of tafluprost monotherapy [6] or timolol monotherapy [7] , and was non-inferior to that of tafluprost combined with timolol [6] .
In this study, the reduction of IOP in patients switched from PGA monotherapy or b-blocker monotherapy was similar to that seen in the phase III studies, confirming superior efficacy of Taf-TFC over PGA or b-blocker monotherapy in this real-world study. Previous studies have shown that some patients exhibit a poor response to various PGAs [11] [12] [13] . Some reports indicate that poor responders to one PGA might respond to another PGA [13] [14] [15] . In this study, there were no obvious differences of the IOP reduction between patients switched from tafluprost, latanoprost, or travoprost, indicating that Taf-TFC reduces the IOP in patients previously treated with any PGA.
Switching to Taf However, once daily Taf-TFC was reported to show non-inferiority to concomitant use of tafluprost (once daily) and timolol (twice daily) [6] . Thus, this study confirmed the phase III clinical results in the daily clinical setting. The formulation of Taf-TFC ophthalmic solution was designed to obtain similar penetration of timolol into the anterior chamber as with once daily timolol gel-forming solution, and this was achieved by adjusting the pH [16] . Penetration of timolol into the anterior chamber is pH dependent and increases with an increase in pH, because timolol is a basic compound. Indeed, penetration of timolol into the anterior chamber was greater after instillation of Taf-TFC than after a single dose of timolol, and almost equal to that obtained with timolol gel-forming solution [16] . This increased penetration of timolol into the anterior chamber with Taf-TFC may explain why its IOP-lowering effect is equal to that of concomitant PGA and b-blocker therapy, which may not be the case for all PGA-TFCs.
There was also a significant IOP-lowering effect when patients were switched from other PGA-TFCs, with a mean IOP reduction of about 1.5 mmHg. Clinically, reduction of the IOP by 1 mmHg is considered to be significant, because the Early Manifest Glaucoma Trial (ClinicalTrials.gov identifier, NCT00000132) revealed an estimated 10% decrease in the risk of progression for each 1 mm of mercury reduction in IOP [17] .
The question about dosing time of PGA-TFCs is under debate. Timolol is recommended to be used in the morning, because the IOP-lowering effect of timolol maleate is weaker with dosing at night compared to that with daytime dosing [18] .
On the other hand, the IOP-lowering effect of PGAs does not change throughout the day [18] and most physicians prefer to dose them in the evening. In addition, the theory on which dosing time is better for PGA-TFCs is still controversial. Takmaz reported that while both morning and evening dosing of Lat-TFC were effective for lowering the IOP, evening dosing was more effective than morning dosing in terms of IOP fluctuation [19] . In contrast, there were no differences reported between morning and evening dosing of Lat-TFC [20] and Tra-TFC [21] . Although no large-scale comparison on the effect of the dosing time is available, the results of this study indicate that both morning and evening dosing for Taf-FDC can be utilized.
Adherence to glaucoma medication is an unsolved problem. In principle, treatment of glaucoma should start with monotherapy using a first-line drug followed by addition of a second-line drug or switching to a fixed combination according to many glaucoma guidelines (Japan Glaucoma Society, European Glaucoma Society, etc.). Concomitant use of two or more ophthalmic solutions may reduce adherence compared to monotherapy [22] , and the physician must evaluate whether a patient is likely to adhere to complicated treatment regimen. Prescription of a fixed combination is an alternative to two different drugs. In this study, adherence to Taf-TFC was generally good, and only six patients (1.9%) reported that compliance was worse than to previous medication. Djafari concluded that the use of fewer medications may improve adherence [22] .
In this study, the compliance rate showed the greatest improvement in patients who decreased the number of separate medications, but the improvement in compliance was not prominent. There were several limitations in this study.
The major limitation of the study is the very short-term data. Unlike an interventional study, there was no control group, and specified examination and drug compliance could not be controlled in this observational study. Since we cannot define further the diagnosis of POAG and NTG, the SD of IOP reduction in this study was larger than in previous interventional studies, such as the phase III clinical trial of Taf-TFC [6] . Despite these limitations, these data reflect the actual real-world usage of Taf-TFC, and thus, our findings can serve as a reference for assessing the future use of Taf-TFC in clinical practice. Even though this study only analyzed short-term data up to 3 months, our results suggest that Taf-TFC is effective for the treatment of glaucoma in a variety of clinical settings. Since glaucoma usually requires chronic treatment, both long-term efficacy and safety data need to be collected and analyzed. This up to 2-year observational study is still ongoing, and the long-term findings will be presented after the data have been analyzed at the end of the study period.
